Oncology

The priority review of inavolisib is for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Quadruple therapies including immunotherapy agents show promise in treating patients with multiple myeloma.

Individuals from a lower socioeconomic group showed more benefits from low-dose CT screening relating to lung cancer survival.

If approved, zanidatamab will be the first HER2-targeted treatment indicated for individuals with this type of biliary tract cancer.

Gender disparities among oncology health care professionals have significant consequences for both the physicians and the patients they treat.

Pharmacists from Mayo Clinic recap some of the latest treatment opportunities to advance patient care in the oncology space.

Although sun-protective measures have been increasing, the incidence of skin cancer has also increased, suggesting better targeted interventions and patient education are needed.

Isatuximab is used in combination with bortezomib, lenalidomide, and dexamethanose.

The authors note further research on technological monitoring methods can help health care providers better optimize patient care and improve nonadherence and nonpersistence.

Speakers at the 2024 Society of Pain and Palliative Care Virtual Conference discussed advanced treatment opportunities for patients with substance use disorder (SUD) and cancer-related pain.

Jodi Taraba, PharmD, MS, BCOP, offers insights on the benefits of involving oncology pharmacists in clinical trial research to advance treatment and care for patients with cancer.

Clinical trials are using AI to handle large and complex volumes of data to develop oncology, cardiovascular, and neurologic compounds and to integrate molecular and imaging data.

Combination treatment of sotorasib plus panitumumab prolongs progression-free survival in those with metastatic colorectal cancer and the KRAS G12C mutation.

Smoking increases exposure to carbon monoxide, and this may be associated with better clinical response to autophagy inhibitors.

Inavolisib was submitted to the FDA for review as a first-line treatment for advanced HR-positive, HER2-negative PIK3CA-mutated breast cancer.

Investigators assessed the efficacy of BsAb5003 in treating multiple myeloma, with the results showing that the therapy may be an effective treatment approach.

Researchers from the University of Leipzig Medical Center identify multiple biomarkers associated with the success of CAR T cell therapy in relapsed multiple myeloma.

As value-based health care models become more widespread, these types of interventions will be important to demonstrate the value of pharmacist-embedded HSSPs.

In 2014, the cobas human papillomavirus test was approved by the FDA for first-line, primary screening in women aged 25 years and older.

Researchers observed that patients aged 80 years and older with acute myeloid leukemia who were treated with venetoclax and a hypomethylating agent had prolonged overall survival.

Both MetS and obesity status have independent and differential associations with breast cancer, and may serve as separate targets for breast cancer prediction and prevention strategies.

As summer approaches, remind patients to go back to basics with sunscreen and self-examinations.

Tarlatamab is a first-in-class immunotherapy that binds to DLL3 tumor cells and CD3 T-cells, to kill DLL3-expressing SCLC.

Candy Peskey highlights the necessary role of oncology pharmacists in patient care and enrollment in clinical trials.

Scott Soefje highlights how oncology pharmacists can advance patient-centered care and drive innovation in clinical research.

The study data demonstrate that higher adiposity in childhood results in less dense breast tissue forming, reducing the risk of breast cancer.

The indication is for adult patients who have received at least 2 prior lines of systemic therapy and is based on the response rate and duration of response shown in a phase 2 trial.

The authors note that the biomarkers found in the blood were involved in inflammatory processes, immune functions, or vascular processes, and may be pre-diagnostic indicators.